Sugi Predict

Sugi Predict / Compounds / SCHEMBL24322190

SCHEMBL24322190

SCHEMBL24322190

Cc1csc(NC(C)C)c1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MELK Q14680 4/20 0.40
▸ MAPK1 P28482 1/20 0.36
▸ FLT3 P36888 7/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAPK10 P53779 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CFTR P13569 1/20 0.35
▸ ADRA2A P08913 1/20 0.34
▸ ADRA2B P18089 1/20 0.34
▸ ADRA2C P18825 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ MAPK8 P45983 1/20 0.33
▸ MAPK9 P45984 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24322196 0.84 MAPT (0.39) MELKMAPTALDH1A1HPGDRAB9A
SCHEMBL24322959 0.81 MAPK8 (0.49) MAPK1MAPTMAPK10ALDH1A1TP53
SCHEMBL14585671 0.80 ADRA2A (0.36) FLT3MAPTMAPK10ALDH1A1TP53
SCHEMBL1930005 0.79 EPHB4 (0.40) MAPK1FLT3MAPTMAPK10ALDH1A1
SCHEMBL16246364 0.77 PTK2 (0.49) FLT3MAPTMAPK10ALDH1A1TP53
SCHEMBL26295499 0.76 EPHB4 (0.39) MAPTMAPK10ALDH1A1TP53HPGD
SCHEMBL7672857 0.74 MAPT (0.44) MAPK1FLT3MAPTMAPK10ALDH1A1
SCHEMBL15965535 0.72 ANO1 (0.38) MAPTMAPK10ALDH1A1TP53SMN1; SMN2
SCHEMBL4167066 0.71 ADRA2A (0.40) MAPTMAPK10ALDH1A1TP53HPGD
SCHEMBL12204339 0.70 EPHB4 (0.36) MAPK1MAPTMAPK10ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 — — US disclosed
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 — — US disclosed
CN-116583283-A CDK inhibitors and their use as pharmaceuticals 普莱鲁德疗法有限公司 2023-08-11 — — CN disclosed
EP-4214213-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS Prelude Therapeutics, Incorporated (US) 2023-07-26 — — EP disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 — — US disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 — — US disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 — — WO disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 MELK 873/4885MAPK1 198/4885FLT3 659/4885
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 MELK 873/4885MAPK1 198/4885FLT3 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.